GN-HEARING
2.4.2020 10:41:08 CEST | Business Wire | Press release
GN Hearing, the global leader in hearing aid technology, today announced the introduction of ReSound Assist Live, a real-time video-enabled hearing care service. At a time when elderly, more vulnerable populations are advised to stay home, this innovative telehealth solution enables people, from the comfort and safety of their home, to connect with their hearing care professional for new hearing aids and care remotely.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200402005306/en/
GN Hearing recognizes that COVID-19 may seriously affect people who use hearing aids due to stricter social distancing measures, ultimately affecting many people’s wellbeing and mental health. Telehealth services can make an important difference in helping people stay connected with loved ones and informed on rapidly changing events while staying at home. People do not have to sacrifice their hearing and can get the help they need to hear better.
With the launch of ReSound Assist Live, people can now have new hearing aids adjusted remotely by their hearing care professional via new at-home video consultations without physically going to a clinic. Additionally, in these difficult times, hearing care professionals can provide new hearing aids for those who have recently completed a hearing test. In collaboration with HearX, a digital health care company focused on mobile hearing screening, testing and video otoscopy, hearing care professionals in the US can also offer drive-through or at-home hearing tests and receive adjustments and counseling via ReSound Assist Live.
“At this critical time, GN Hearing is as committed as always to helping the hearing community where it’s most needed. For many people, staying in touch with loved ones on the phone and online demands great hearing abilities, so getting access to hearing care support is crucial, particularly for those in self-isolation when communicating is imperative for an individual’s wellbeing,” says Gitte Aabo, CEO and President of GN Hearing.
ReSound Assist Live is an update to ReSound Assist, which already lets people request and receive adjustments to their hearing aids remotely, but the new telehealth tech goes further, enabling live video consultations with hearing care professionals for support wherever they are. This allows in-person support over live video and remote fitting of hearing aids all via the ReSound Smart 3D™ app.
“We expect that the introduction of ReSound Assist Live will help more hearing aid users and their hearing care professionals connect via our innovative remote solutions that work for them, regardless of what’s going on in their lives, how much mobility they have during this difficult time, and in the future,” Gitte Aabo continues.
ReSound Assist Live is available on April 2, 2020 in the US, Canada, the U.K., Germany, Australia, New Zealand and Singapore, and globally from May 1. At-home and drive-through hearing tests will be offered shortly in the US.
- ENDS -
NOTES TO EDITORS
ReSound Assist Live enables individualized care from anywhere
New ReSound Assist Live is an extension of the existing ReSound Assist remote fine-tuning services and can be accessed via video call on the ReSound Smart 3D app. It is the only fitting software which offers comprehensive live video and remote adjustment options.
ReSound Assist already lets people request and receive adjustments to their hearing aids remotely, but ReSound Assist Live goes further, enabling them to speak directly to their hearing care professional over a live link. This means they can benefit from instant access to the highest level of care at a convenient time and place.
About ReSound
ReSound hearing aids, available from leading hearing care professionals, have set worldwide standards for quality and intuitive technology. ReSound was the first hearing aid brand to be Made for iPhone and pioneered the development of 2.4 GHz wireless technology. The introduction of the sixth generation of this technology with ReSound LiNX QuattroTM demonstrates that ReSound is the absolute leader in the industry. Featuring award winning technology, ReSound has been trusted for decades by people with hearing loss and their caregivers around the world.
About GN Group
The GN Group enables people to Hear More, Do More and Be More through its intelligent hearing, audio and video collaboration solutions. Inspired by people and driven by our innovation leadership, we leverage technological synergies between our hearing and audio divisions to deliver unique and increasingly individualized user experiences in our products and solutions.
150 years ago, GN was founded with a truly innovative and global mindset. Today, we honor that legacy with world-leading expertise in the human ear, sound and video processing, wireless technology, miniaturization and collaborations with leading technology partners. GN's solutions are marketed by the brands ReSound, Beltone, Interton, Jabra, BlueParrott and FalCom in 100 countries. Founded in 1869, the GN Group employs 6,500 people and is listed on Nasdaq Copenhagen (GN.CO).
Visit our homepage GN.com, get to know our innovation and leadership , and connect with us on LinkedIn , Facebook and Twitter .
© 2020 GN Hearing A/S. All rights reserved. ReSound is a trademark of GN Hearing A/S. Apple, the Apple logo, iPhone, iPad and iPod touch are trademarks of Apple Inc., registered in the U.S. and other countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200402005306/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom